Aquestive Therapeutics Settles Patent Infringement Case with Par Pharmaceuticals

by

Call 1 (888) 460-6556 to speak with a counselor.

WARREN, N.J., May 14, 2018 — (Healthcare Sales & Marketing Network) — Aquestive Therapeutics, Inc., today announced a settlement agreement has been reached resolving patent litigation related to SUBOXONE® (buprenorphine and naloxone) Sublingual Film… Biopharmaceuticals, Drug Delivery, Generics, Litigation Aquestive Therapeutics, Par Pharmaceuticals, SUBOXONE, buprenorphine, naloxo (Source: HSMN NewsFeed)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

Previous post:

Next post: